Sanofi recalls heartburn drug over cancer risks

Sanofi is recalling Zantac in the U.S. a month after the FDA warned the heartburn drug contained a possible carcinogen.

Several of the country's largest retailers, including Walmart, CVS and Walgreens, pulled Zantac and other ranitidine products off their shelves several weeks ago.

Sanofi said it is initiating the recall because of "inconsistencies in preliminary test results of the active ingredient used in the U.S," according to a news release.

Sanofi's decision to pull Zantac comes as regulators are trying to figure out why N-nitrosodimethylamine, a possible carcinogen, was found in some ranitidine medicines. A growing number of regulators around the world have also either banned the drugs or asked manufacturers to conduct recalls.

Read the full news release here.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

>